SCHEMBL30438580

SCHEMBL30438580

CC(C)(C)[S+]([O-])NC(c1ccc(OC(F)F)cc1)C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE2A O00408 6/20 0.36
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
ALOX15 P16050 2/20 0.33
GFER P55789 1/20 0.33
ADAM17 P78536 1/20 0.33
ADRB3 P13945 1/20 0.32
HSD17B2 P37059 1/20 0.32
MAPT P10636 3/20 0.32
NPC1 O15118 1/20 0.32
ALDH1A1 P00352 1/20 0.32
RAB9A P51151 1/20 0.32
EPHX2 P34913 1/20 0.32
PKM P14618 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
MAPK1 P28482 1/20 0.31
DRD1 P21728 1/20 0.30
LMNA P02545 1/20 0.30
HTT P42858 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31529514 1.00 PDE2A (0.36) PDE2AMEN1KMT2AALOX15GFER
SCHEMBL25421880 0.84 PDE2A (0.39) PDE2AMAPTALDH1A1EPHX2L3MBTL1
SCHEMBL31529511 0.84 PDE2A (0.39) PDE2AMAPTALDH1A1EPHX2L3MBTL1
SCHEMBL29248358 0.84 PDE2A (0.39) PDE2AMAPTALDH1A1EPHX2L3MBTL1
SCHEMBL29220620 0.82 KMT2A (0.42) PDE2AMEN1KMT2AALOX15GFER
SCHEMBL29220619 0.82 KMT2A (0.42) PDE2AMEN1KMT2AALOX15GFER
SCHEMBL24775053 0.82 KMT2A (0.42) PDE2AMEN1KMT2AALOX15GFER
SCHEMBL4934513 0.82 KMT2A (0.42) PDE2AMEN1KMT2AALOX15GFER
SCHEMBL955811 0.82 KMT2A (0.42) PDE2AMEN1KMT2AALOX15GFER
SCHEMBL30108487 0.82 KMT2A (0.42) PDE2AMEN1KMT2AALOX15GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4436955-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS Lario Therapeutics Limited (GB) 2024-10-02 EP disclosed
WO-2023094830-A1 SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS LARIO THERAPEUTICS LIMITED (GB) 2023-06-01 WO disclosed